Fig. 4: Flow cytometric analysis. | British Journal of Cancer

Fig. 4: Flow cytometric analysis.

From: Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design

Fig. 4

It shows the panel of AlproTox WT, HB and NB fusions antigen-specific binding at 1 µg/mL in PSMA-positive (LNCaP, C4-2) and CD3-positive cells (Jurkat) detected by an anti-human serum antibody (b–d). No shifts in fluorescence were detected in non-expressing CD3 or PSMA (PC3, Du-145) cells. Secondary antibody without primary antibody was used to determine background intensity. PSMA and CD3 expression was verified (a) with an anti-PSMA PE-conjugated antibody (ab77228) and an anti-CD3 FITC-conjugated antibody (21850033), respectively.

Back to article page